[Cyclooxygenase inhibitors: a never ending story?].
Macrì
Rocco
R
Commissione Terapeutica Ospedaliera, già Primario Cardiologo U.O. di Cardiologia del Presidio Ospedaliero di Carrara. macrirocco@virgilio.it
Manfredi
Carlo
C
D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects / Q000191:economics; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000378:metabolism / Q000494:pharmacology; D017277:Drug Approval; D005060:Europe; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects; D007558:Italy; D007783:Lactones / Q000009:adverse effects / Q000191:economics; D016365:Liability, Legal / Q000191:economics; D011451:Prostaglandin-Endoperoxide Synthases / Q000187:drug effects / Q000378:metabolism*; D020033:Protein Isoforms; D011720:Pyrazoles / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects / Q000191:economics; D013781:Texas; D014481:United States; D014486:United States Food and Drug Administration; D000096926:Benzenesulfonamides
D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D007783:Lactones; D011451:Prostaglandin-Endoperoxide Synthases; D020033:Protein Isoforms; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides